New CEO brings commercial nous to NetScientific
This article was originally published in Clinica
Executive Summary
NetScientific, the UK group which invests in biomedical and healthcare companies, has appointed François Martelet as CEO and board director. Dr Martelet, who will join the group on 8 June, was previously senior advisor to the CEO and interim senior vice president at biotech company Stallergenes. His 20-plus years’ of commercial experience in the biopharma industry will come in useful as a number of NetScientific’s portfolio companies start entering the commercialization phase. NetScientific has invested in several IVD companies, such as liquid biopsy technology developer Vortex Biosciences, liver disease diagnosis specialist Glycotest and ProAxsis, which is developing point of care tests for chronic conditions.
You may also be interested in...
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Nose For A Good Tech? Philips Adds Nasal Alar Pulse Oximetry To Monitoring Portfolio
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.